Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.

Summary

In eosinophilic COPD patients already on triple inhaled therapy, mepolizumab reduced the annualized rate of moderate/severe exacerbations (RR 0.79) and prolonged time to first exacerbation (HR 0.77), with similar adverse event rates versus placebo. Health-related quality of life and symptom measures did not significantly differ.

Key Findings

• Annualized moderate/severe exacerbations were lower with mepolizumab vs placebo (0.80 vs 1.01 events/year; RR 0.79; 95% CI 0.66–0.94; P=0.01).
• Time to first moderate/severe exacerbation was longer with mepolizumab (median 419 vs 321 days; HR 0.77; 95% CI 0.64–0.93; P=0.009).
• No significant between-group differences in HRQoL and symptom measures; adverse events were similar.

Clinical Implications

Consider mepolizumab as an add-on for COPD patients with eosinophils ≥300/µL who remain exacerbation-prone despite triple therapy. Expect reduced exacerbation rates without clear HRQoL gains; evaluate cost-effectiveness and patient selection.

Limitations

• No significant improvement in HRQoL/symptom scores; multiplicity limited inferences on later secondary endpoints.
• Generalizability limited to high-eosinophil COPD on triple therapy; industry-sponsored trial.

Future Directions

Head-to-head and cost-effectiveness studies versus other biologics; biomarker thresholds and response predictors; impact on severe outcomes (ED visits/hospitalizations) and steroid-sparing effects.